Monte Rosa Therapeutics (GLUE) Operating Expenses (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Operating Expenses of $54.2 million for Q1 2026, up 32.65% year-over-year from $40.9 million in Q1 2025, and up 3.33% quarter-over-quarter from $52.5 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Operating Expenses (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $54.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 32.65% year-over-year to $54.2 million; the TTM figure through Mar 2026 stood at $191.2 million (up 18.32% YoY), while the FY2025 annual figure was $177.9 million, up 13.49% from the prior year.
- Operating Expenses for Q1 2026 stood at $54.2 million, up from $52.5 million in the prior quarter.
- The five-year high for Operating Expenses was $54.2 million in Q1 2026, with the low at $24.3 million in Q1 2022.
- The 5-year median for Operating Expenses is $37.0 million (2023), against an average of $37.9 million.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 111.25% in 2022, then fell 3.31% in 2024.
- Monte Rosa Therapeutics' Operating Expenses stood at $32.5 million in 2022, then advanced by 7.31% to $34.9 million in 2023, then jumped by 36.66% to $47.6 million in 2024, then grew by 10.19% to $52.5 million in 2025, then grew by 3.33% to $54.2 million in 2026.
- Business Quant data shows GLUE's Operating Expenses at $54.2 million in Q1 2026, $52.5 million in Q4 2025, and $45.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 58.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.10 Mn |
| Mar 31, 2026 | 54.24 Mn |
| Dec 31, 2025 | 52.50 Mn |
| Sep 30, 2025 | 45.74 Mn |
| Jun 30, 2025 | 38.75 Mn |
| Mar 31, 2025 | 40.89 Mn |
| Dec 31, 2024 | 47.64 Mn |
| Sep 30, 2024 | 35.74 Mn |
| Jun 30, 2024 | 37.34 Mn |
| Mar 31, 2024 | 36.01 Mn |
| Dec 31, 2023 | 34.86 Mn |
| Sep 30, 2023 | 36.97 Mn |
| Jun 30, 2023 | 37.22 Mn |
| Mar 31, 2023 | 34.26 Mn |
| Dec 31, 2022 | 32.49 Mn |
| Sep 30, 2022 | 28.36 Mn |
| Jun 30, 2022 | 27.23 Mn |
| Mar 31, 2022 | 24.30 Mn |
| Dec 31, 2021 | 23.39 Mn |
| Sep 30, 2021 | 19.87 Mn |